Noema's basimglurant gains US orphan status in trigeminal neuralgia, adding to Fast Track
The Swiss biotech's oral mGluR5 drug candidate now holds two FDA regulatory designations for the same pain indication, though no clinical data accompanied the announcement.
16 Nov 2026 · Noema Pharma AG · Company news
Noema Pharma has secured a second US regulatory designation for basimglurant, its investigational therapy for trigeminal neuralgia. The Swiss company said on 16 November 2026 that the FDA had granted the drug orphan status. The compound was previously coded NOE-101.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More IndustryAll →
Industry
iMDx Pauses FDA De Novo Review of GraftAssureDx Kidney Rejection Test, Plans January Response
16 Nov 2026 · Insight Molecular Diagnostics Inc. IMDX · Company news
Industry
Cumberland to file ifetroban NDA for Duchenne cardiomyopathy under FDA rolling submission
16 Nov 2026 · Cumberland Pharmaceuticals Inc CPIX · Company news
Industry
FDA sets 25 March 2027 goal date for Unicycive's resubmitted oxylanthanum carbonate application
16 Nov 2026 · Unicycive Therapeutics, Inc. UNCY · Company news
Industry
Sono Group updates share counts ahead of 11 December redomiciliation vote
16 Nov 2026 · Sono Group N.V. SSM · Company news
Industry
FDA issues complete response letter for Summit's ivonescimab in EGFR-mutant NSCLC
16 Nov 2026 · Summit Therapeutics Inc. SMMT · Company news
Industry
XORTX Therapeutics warns of going-concern doubt as cash falls to $318,846
16 Nov 2026 · XORTX Therapeutics Inc. XRTX · Company news